MedTrace Logo

Study to Evaluate the AIO-001 in Healthy Participants

NCT06170827 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-08-14

Study results available
· View outcomes & findings →

Summary

This goal of the open-label single dose study is to evaluate and compare the safety, tolerability, pharmacokinetic (PK), and immunogenicity of AIO-001 using two different formulations in 16 healthy volunteers.

Conditions

  • Respiratory Disease

Interventions

DRUG

AIO-001

AIO-001 Solution for SC injection.

Sponsors & Collaborators

  • Aiolos Bio, Inc., a GSK Company

    collaborator UNKNOWN

  • Syneos Health

    lead OTHER

Principal Investigators

  • Principal Investigator · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2024-07-15
Completion
2024-07-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06170827 on ClinicalTrials.gov